An NHS worker has become the first person to be recruited for the final stage trial of a coronavirus vaccine.
Claire Cole, head of research delivery at Manchester University NHS Foundation Trust (MFT), is the first person in the world to be consented into phase three of the study to test the safety and effectiveness of the two-dose vaccine regimen developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Ms Cole is one of 6,000 volunteers in the UK, and of 30,000 worldwide, being recruited for the study, taking place at 17 National Institute for Health Research sites in the UK – including in Manchester.
She said: “Although I have worked in health research for a number of years, I never cease to be amazed by the life-changing, and sometimes lifesaving, impact research can have.
“This has never been truer than during the Covid-19 pandemic, where I have seen first-hand how rapidly clinical research can be translated into treatments for our patients.
“I wholeheartedly believe in the importance of taking part in research and am honoured to be the first person in the world to be recruited to the study, and one of the first to receive the vaccine, as part of this vitally important coronavirus vaccine trial.”